Cellectis S.A. (NASDAQ:CLLS) saw a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 394,617 shares, a drop of 27.3% from the May 15th total of 542,908 shares. Based on an average trading volume of 58,543 shares, the short-interest ratio is presently 6.7 days. Currently, 1.1% of the shares of the company are short sold.
A number of equities research analysts have commented on the stock. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Cellectis in a research note on Saturday, June 3rd. Instinet assumed coverage on shares of Cellectis in a research note on Wednesday, March 1st. They set a “buy” rating and a $49.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of Cellectis in a research report on Tuesday, February 28th. They set an “outperform” rating on the stock. Zacks Investment Research cut shares of Cellectis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 4th. Finally, Nomura assumed coverage on shares of Cellectis in a research report on Wednesday, March 1st. They set a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Cellectis presently has an average rating of “Buy” and an average target price of $39.60.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ellington Management Group LLC acquired a new position in shares of Cellectis during the fourth quarter worth about $210,000. DSC Advisors L.P. acquired a new position in shares of Cellectis during the fourth quarter worth about $975,000. Vident Investment Advisory LLC raised its position in shares of Cellectis by 68.3% in the fourth quarter. Vident Investment Advisory LLC now owns 42,498 shares of the biotechnology company’s stock worth $720,000 after buying an additional 17,244 shares during the period. Eqis Capital Management Inc. acquired a new position in shares of Cellectis during the first quarter worth about $202,000. Finally, Trexquant Investment LP acquired a new position in shares of Cellectis during the first quarter worth about $214,000. Hedge funds and other institutional investors own 16.25% of the company’s stock.
Shares of Cellectis (NASDAQ:CLLS) opened at 23.11 on Friday. Cellectis has a 52-week low of $16.09 and a 52-week high of $29.09. The stock’s 50 day moving average is $24.11 and its 200 day moving average is $21.44. The company’s market cap is $816.59 million.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229441/cellectis-s-a-clls-short-interest-down-27-3-in-may.html
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.